mySugr Passes 1 Million Users

Incredible milestone firmly secures company as the world’s most popular digital diabetes platform

mySugr announced today that the company recently passed the 1 million registered user mark firmly securing the company as the world’s most popular digital diabetes platform. This milestone shows remarkable growth since the company’s start in 2012.

mySugr was created by four passionate entrepreneurs, two of whom live with type 1 diabetes. Five short years later, the company has more than 45 employees in Vienna and a second office in San Diego. The company specializes in app-based, all-around care for people with diabetes. Its apps and services are mutually compatible solutions to ease the daily grind of diabetes. The mySugr App has an average 4.6-star rating in the App and Play Stores and there are even multiple users who’ve tattooed the mySugr logo onto their body!

“We’re thrilled to be the first mobile diabetes platform to reach such a huge landmark, and it’s awesome to know we’re helping so many people.”  said Frank Westermann, CEO & co-founder of mySugr,

“I’m even more excited about what’s yet to come! We’re still gaining momentum and have many innovative products launching soon.” mySugr has a number of preferred device integrations with industry-leaders such as Roche, Medtronic, and Abbott, as well as partnerships with pharma companies like Novo Nordisk. mySugr is also working with large payers in Europe and is in discussions with additional insurance companies around the world.

About mySugr
Founded in 2012, mySugr specializes in app-based, all-around care for people with diabetes. The company has offices in San Diego, California and Vienna, Austria with more than 45 employees across both locations.

The company’s digital diabetes solutions showcase a stand-out user experience that combines diabetes coaching, therapy management, automated data tracking, and seamless integration with a growing number of medical devices. The mySugr App is available in 52 countries and 13 languages. For more information, please visit and

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)